This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
by Zacks Equity Research
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
by Zacks Equity Research
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
Orexigen Struggles as Contrave Commercialization Costs Rise
by Zacks Equity Research
Orexigen (OREX) hurt by higher commercialization costs related to Contrave.
Implied Volatility Surging for Orexigen (OREX) Stock Options
by Zacks Equity Research
Investors in Orexigen Therapeutics (OREX) need to pay close attention to the stock based on moves in the options market lately.
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up
by Zacks Equity Research
Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.
Orexigen's (OREX) Contrave Sales Improving on Promotions
by Zacks Equity Research
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
Why These 4 Biotech Stocks May Not Lose Momentum Soon
by Zacks Equity Research
The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
by Zacks Equity Research
Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.
Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Orexigen (OREX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
by Zacks Equity Research
Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
by Zacks Equity Research
On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.
Orexigen Inks Commercialization Deal for Contrave, Stock Up
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
by Zacks Equity Research
Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.
Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue?
by Zacks Equity Research
Orexigen Therapeutics, Inc. (OREX) has been on the move lately as the stock has risen by 74.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
Celgene Issues Preliminary 2016 Results, Lifts 2017 View
by Zacks Equity Research
Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
by Zacks Equity Research
Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The Medicines Co LDL-Lowering Drug Positive in Phase II
by Zacks Equity Research
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
by Zacks Equity Research
On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).